Your session is about to expire
← Back to Search
Beta-2 Agonist
Test 0.09 mg for Asthma
Phase 3
Waitlist Available
Research Sponsored by Aurobindo Pharma Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over a period of 4 weeks
Awards & highlights
Study Summary
Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg
Eligible Conditions
- Asthma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ over a period of 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over a period of 4 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Post-dose PD20
Trial Design
5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Test 0.18 mgExperimental Treatment2 Interventions
Group II: Test 0.09 mgExperimental Treatment2 Interventions
Group III: Reference 0.09 mgActive Control2 Interventions
Group IV: Reference 0.18 mgActive Control2 Interventions
Group V: Zero dose:Placebo Group2 Interventions
Find a Location
Who is running the clinical trial?
Aurobindo Pharma LtdLead Sponsor
7 Previous Clinical Trials
26,457 Total Patients Enrolled
1 Trials studying Asthma
1,550 Patients Enrolled for Asthma
Joseph Marialouis, MDStudy DirectorAurobindo Pharma Ltd
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger